deucrictibant
AssetAlso PHA-022121, PHA-121, PHVS-719
Blocks bradykinin B2 receptors to relieve bradykinin-mediated angioedema attacks.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- BDKRB2
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Hereditary angioedema
Phase 3, thelancet.com, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.